問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Digestive System Department

更新時間:2023-09-19

鄭斌男Cheng, Pin-Nan
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

篩選

List

74Cases

2005-10-01 - 2008-07-01

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2018-06-01 - 2026-08-31

Phase III

Active
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation
  • Condition/Disease

    Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation

  • Test Drug

    Nivolumab

Participate Sites
12Sites

Recruiting1Sites

Terminated10Sites

林錫銘
Linkou Chang Gung Medical Foundation

Digestive System Department

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

2025-12-01 - 2032-08-02

Others

Not yet recruiting
AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
  • Condition/Disease

    Primary Biliary Cholangitis

  • Test Drug

    Capsules

Participate Sites
7Sites

Not yet recruiting7Sites

2023-02-15 - 2025-06-30

Phase I

Completed
A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)
  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    注射劑 注射劑

Participate Sites
10Sites

Terminated10Sites

2024-11-15 - 2032-04-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-06-01 - 2026-12-31

Phase II

Active
A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Precirrhotic Nonalcoholic Steatohepatitis
  • Condition/Disease

    Non-alcoholic Fatty Liver Disease

  • Test Drug

    MK-6024

Participate Sites
7Sites

Recruiting7Sites

2020-08-17 - 2023-12-12

Phase I/II

Completed
A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors
  • Condition/Disease

    Advanced/Metastatic Solid Tumors

  • Test Drug

    V937;吉舒達®/Keytruda®

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

2008-01-15 - 2009-12-31

Phase I

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2017-05-01 - 2025-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-11-09 - 2032-11-22

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites